Age-related macular degeneration primarily attacks the macula, the central region of the retina responsible for sharp, central vision necessary for reading, driving, and recognizing faces. The disease progresses through stages, with the intermediate form serving as a critical tipping point before advanced deterioration. Advanced AMD manifests as either geographic atrophy (GA or dry AMD), characterized by the death of light-sensitive photoreceptor cells, or neovascular (wet) AMD, marked by abnormal blood vessel growth, which often leads to rapid and severe vision loss.

The Liverpool study followed 2,000 diabetic individuals over the age of 55 attending routine diabetic eye screenings. Researchers rigorously analyzed retinal photographs taken over a five-year period to detect and classify AMD according to severity. Uniquely, this research employed direct photographic grading rather than relying on secondary data sources such as diagnostic codes or insurance claims, increasing the precision and reliability of their findings.

The results were remarkable. Patients on metformin displayed a 37% lower likelihood of developing intermediate AMD compared to those not using the medication, with an odds ratio of 0.63 (95% confidence interval 0.43 to 0.92). This statistically significant reduction highlights metformin’s potential as a prophylactic agent in retarding macular degeneration progression. It suggests that metformin, beyond its established glycemic control properties, might exert protective effects on retinal health.

Metformin’s mechanisms of action may underlie its protective role in AMD. Known for its ability to suppress hepatic glucose production, metformin also exhibits antioxidant and anti-inflammatory properties. It enhances mitochondrial function and promotes cellular housekeeping processes such as autophagy, crucial for mitigating oxidative stress—a key driver in AMD pathology. These multifaceted cellular benefits may help preserve retinal pigment epithelium integrity and photoreceptor survival, thwarting disease advancement.

Current treatments for AMD remain limited and onerous. Geographic atrophy has no available cure or effective therapy in the UK or much of Europe, leaving millions of patients with progressive vision loss. Treatments for wet AMD involve repeated, often monthly intraocular injections of anti-VEGF agents, which are invasive, costly, and burdensome to patients and healthcare systems alike. A widely accessible oral medication like metformin could revolutionize AMD care by providing a safe, affordable, and non-invasive alternative.

This study is particularly timely given the burgeoning global burden of AMD and the escalating costs associated with its management. In the UK alone, AMD-related healthcare and social costs exceed £11 billion annually, underscoring the urgent need for innovative therapeutic strategies. If metformin’s efficacy can be validated in randomized clinical trials specifically targeting AMD patients, it could significantly alleviate this economic strain while preventing millions from losing their sight.

The lead investigator, Dr. Nick Beare, emphasized the profound implications of the findings, noting that most individuals with AMD currently face little hope for effective treatment. “This is a major breakthrough,” Dr. Beare stated. “Our next critical step is to conduct clinical trials to confirm whether metformin can serve as a viable treatment to preserve vision in AMD sufferers. Given metformin’s well-established safety profile and affordability, the drug has enormous potential to alter the landscape of AMD therapy and save countless people’s sight.”

Historically, hints of metformin’s benefits in AMD have surfaced through retrospective analyses using insurance databases and general practice medical records, but these lacked the granularity of direct retinal imaging. This Liverpool study’s methodological rigor, involving direct image-based grading, provides a more definitive assessment of metformin’s role in modifying AMD risk, elevating the quality of evidence to a new standard.

Moreover, metformin’s anti-aging effects have intrigued researchers across disciplines. Its capacity to modulate cellular energy metabolism and reduce systemic inflammation aligns well with emerging theories that view AMD as a complex, multifactorial disease intertwined with age-related cellular decline. This broader perspective supports the plausibility that metformin’s systemic benefits might extend to ocular tissues, offering a multifaceted approach to combating retinal degeneration.

For patients already on metformin for diabetes, these findings offer reassurances that their medication might confer protective ocular benefits beyond glucose regulation. For non-diabetic individuals, however, it raises the prospect that metformin could be repurposed as a preventative or therapeutic agent in AMD, pending formal clinical validation. Such a development would represent a paradigm shift in ophthalmology, transforming the management of one of the leading causes of blindness worldwide.

In conclusion, the University of Liverpool’s study marks a significant advance in our understanding of AMD and metformin’s potential utility beyond diabetes care. By demonstrating a clear association between metformin use and a reduced risk of intermediate AMD development, the research opens exciting new avenues for prevention and treatment. With clinical trials on the horizon, the hope is that metformin may soon help preserve vision and improve quality of life for millions vulnerable to this devastating disease.

Subject of Research: People
Article Title: [Information not provided in the source]
News Publication Date: 03 February 2026
Web References: [Information not provided in the source]
References: [Information not provided in the source]
Image Credits: [Information not provided in the source]

Keywords: Ophthalmology, Vision disorders, Age-related macular degeneration, Metformin, Diabetes, Retinal diseases, Medical specialties

Age-related macular degeneration, particularly its advanced atrophic form known as geographic atrophy (GA), stands as the foremost cause of irreversible blindness among older populations worldwide. The degeneration involves the destruction of photoreceptors in the macula, the small but critical region of the retina responsible for sharp, central vision. This leads to the progressive worsening of visual acuity, severely impacting daily activities such as reading and recognizing faces for over five million individuals globally. Until now, no treatment could reverse this loss or restore central vision.

The international, multi-center PRIMAvera clinical trial, co-led by distinguished ophthalmologists José-Alain Sahel, Daniel Palanker, and Frank Holz, examined the efficacy of the PRIMA implant in 38 participants aged 60 and older across 17 sites in Europe. Sahel, based at the UPMC Vision Institute, Palanker from Stanford University, and Holz from the University of Bonn, pooled their expertise to analyze outcomes following one year of device usage, highlighting a paradigm shift in the management of AMD.

Remarkably, among the 32 participants who completed a full 12-month follow-up, an overwhelming 81% demonstrated clinically meaningful improvements in visual acuity, while 84% reported using prosthetic vision for functional tasks such as reading numbers and words in their everyday environments. Quantitatively, the average improvement amounted to 25 letters on the standard eye chart, which translates to an approximate five-line gain in vision, underscoring the implant’s profound functional impact.

The PRIMA system is a marvel of biomedical engineering designed to replace the lost photoreceptor function through a compact, wireless 2×2 mm subretinal implant. Developed initially by Dr. Palanker, the implant converts projected near-infrared light into precisely calibrated electrical stimuli that activate the residual retinal neurons. The process begins with a miniature camera mounted on specially crafted glasses, capturing real-time images and transmitting them wirelessly to the implant beneath the retina where the bioelectronic conversion occurs.

Unlike conventional vision restoration approaches, the PRIMA device bypasses the damaged photoreceptors and directly stimulates the inner retinal circuitry. This bioelectronic retina replacement leverages the remaining retinal structure to transmit visual information to the optic nerve and subsequently to the brain’s visual cortex, reestablishing a functional visual pathway. Moreover, patients can customize zoom and contrast settings, optimizing the quality of prosthetic vision to meet their individual needs and visual preferences.

Across the trial cohort, post-surgical recovery was exemplary, with all procedure-related adverse effects resolving within the first year. The visual gains were substantial and consistent, with the most dramatic case achieving an extraordinary 59-letter improvement, equivalent to twelve lines on the eye chart—a transformative functional restoration that exceeds the expectations of previous experimental interventions.

While achieving full 20/20 vision restoration remains beyond the current capabilities of the PRIMA system, researchers at UPMC and collaborators actively pursue enhancements through combined technological and biomedical advancements. These efforts aim to surpass legal blindness criteria, dramatically elevating patients’ independence and quality of life beyond current thresholds, signaling a future of renewed hope for those afflicted with vision loss from AMD.

This early success has galvanized regulatory pathways, prompting Science Corporation, the device manufacturer, to seek clinical authorization for widespread use in Europe and the United States. Notably, UPMC has been at the forefront, implanting the PRIMA system in the United States as early as 2020 within an initial trial led by associate professor Joseph Martel, evidencing the accelerating translation from research breakthroughs to clinical implementation.

In addition to the leading institutions involved, the study’s collaborative authorship spans notable eye centers including the Adolphe de Rothschild Foundation Hospital in Paris, Moorfields Eye Hospital in London, and the University of Rome Tor Vergata, reflecting a robust multinational effort in addressing one of ophthalmology’s greatest challenges.

Funded primarily by Science Corporation alongside support from the National Institute for Health and Care Research Biomedical Research Centre and UCL Institute of Ophthalmology, the study exemplifies a model of synergistic public-private research endeavors driving innovative solutions in medical science.

The clinical implications of this technological triumph extend beyond AMD, potentially heralding a new era in neuroprosthetics and vision science. The PRIMA system’s design embodies the convergence of bioengineering, ophthalmology, and neuroscience, opening avenues for future applications in other retinal diseases and sensory impairments, thereby expanding the horizon of restorative medicine.

As the global population ages, the burden of vision loss is expected to rise, amplifying the necessity for scalable, effective treatments. This breakthrough positions the PRIMA implant as a cornerstone technology with the capacity to transform the landscape of treatment options for degenerative retinal diseases, offering patients not just incremental improvements, but the restoration of meaningful vision and autonomy.

Subject of Research: People
Article Title: Vision Restoration with the PRIMA System in Geographic Atrophy Due to AMD
News Publication Date: 20-Oct-2025
Web References: https://www.nejm.org/doi/full/10.1056/NEJMoa2501396
References: Disclosure forms by the authors are available with the full text at NEJM.org
Image Credits: UPMC

Keywords: Macular degeneration, Vision disorders, Prosthetics, Retina, Ophthalmology, Blindness